| Analysis | Metabolite Name | Measured Value | Units | Genotype |
|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7059 | Normalized/scaled raw area counts | WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7286 | Normalized/scaled raw area counts | WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7356 | Normalized/scaled raw area counts | EXOC5_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7563 | Normalized/scaled raw area counts | EXOC5_KD |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7731 | Normalized/scaled raw area counts | IFT88_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7875 | Normalized/scaled raw area counts | EXOC5_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8138 | Normalized/scaled raw area counts | IFT88_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8369 | Normalized/scaled raw area counts | WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8591 | Normalized/scaled raw area counts | WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8823 | Normalized/scaled raw area counts | EXOC5_KD |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8904 | Normalized/scaled raw area counts | IFT88_KO_WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8999 | Normalized/scaled raw area counts | IFT88_KO_WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9064 | Normalized/scaled raw area counts | EXOC5_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9333 | Normalized/scaled raw area counts | WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9368 | Normalized/scaled raw area counts | EXOC5_KD |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9601 | Normalized/scaled raw area counts | WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.977 | Normalized/scaled raw area counts | IFT88_KO_WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9915 | Normalized/scaled raw area counts | IFT88_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0085 | Normalized/scaled raw area counts | IFT88_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0131 | Normalized/scaled raw area counts | IFT88_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0218 | Normalized/scaled raw area counts | IFT88_KO_WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0367 | Normalized/scaled raw area counts | IFT88_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0399 | Normalized/scaled raw area counts | EXOC5_OE |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0696 | Normalized/scaled raw area counts | EXOC5_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0945 | Normalized/scaled raw area counts | IFT88_KO_WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0954 | Normalized/scaled raw area counts | EXOC5_KD |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1366 | Normalized/scaled raw area counts | EXOC5_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1673 | Normalized/scaled raw area counts | EXOC5_KD |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1717 | Normalized/scaled raw area counts | EXOC5_KO |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2023 | Normalized/scaled raw area counts | EXOC5_OE |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2029 | Normalized/scaled raw area counts | IFT88_KO_WT |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2185 | Normalized/scaled raw area counts | EXOC5_KD |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2241 | Normalized/scaled raw area counts | EXOC5_OE |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.4491 | Normalized/scaled raw area counts | EXOC5_OE |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.4576 | Normalized/scaled raw area counts | EXOC5_OE |
| Reversed phase POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.7031 | Normalized/scaled raw area counts | EXOC5_OE |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|